Skip to content

Subscribe Follow on LinkedIn

Archive

November 2025

26: Affinia closes $40m Series C: CEO Rick Modi explains how low-dose gene therapy capsids could cure cardiomyopathy

November 2025

17: Jefferies Global Healthcare Conference in London

November 2025

13: New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

November 2025

13: Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

November 2025

13: enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

November 2025

12: Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

November 2025

12: Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights

November 2025

12: enGene Announces Proposed Public Offering of Common Shares

November 2025

12: Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

November 2025

12: Neochromosome and GlobalBio Launch Pre-Transformed Antibody Libraries in Switchable Yeast Platform

November 2025

11: Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

November 2025

11: Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

November 2025

10: Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

November 2025

10: SpyGlass Pharma Announces Positive 36-Month First-in-Human and 3-Month Phase I/II Trial Results for Its Novel BIM-IOL System

November 2025

10: enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

November 2025

10: Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

November 2025

8: Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

November 2025

7: Guardant Health to Participate in Upcoming Investor Conferences

November 2025

7: Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

November 2025

6: Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

November 2025

6: Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 2025

6: enGene to Participate in Upcoming Investor Conferences

November 2025

6: Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 2025

6: New Study Validates Guardant Reveal Blood Test’s Effectiveness in Monitoring Chemotherapy Response

November 2025

6: Seer Reports Third Quarter 2025 Financial Results

November 2025

5: FDA approvals - October 2025

November 2025

5: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 2025

5: Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

November 2025

5: Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 2025

5: Keros Therapeutics Reports Third Quarter 2025 Financial Results

November 2025

5: Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

November 2025

5: Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

November 2025

5: Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

November 2025

5: Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

November 2025

4: Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

November 2025

4: Recursion to Participate in Upcoming Investor Conferences

November 2025

4: How Epicrispr are leading the first epigenetic editing trial for muscular dystrophy

November 2025

4: Geron Corporation to Present at Upcoming Investor Conferences

November 2025

4: Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

November 2025

4: enGene Named a BioSpace 2026 Best Places to Work Winner

November 2025

4: Guardant Health Announces Proposed Public Offering of Common Stock

November 2025

4: Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

November 2025

3: Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

November 2025

3: Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

November 2025

3: Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

November 2025

3: Legend Biotech Announces 9 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

November 2025

3: Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results

November 2025

3: Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

November 2025

2: Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

October 2025

31: Perspective Therapeutics to Participate in Upcoming November Conferences

October 2025

30: Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 2025

30: Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting

October 2025

30: Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

October 2025

29: Seer to Participate in Upcoming November Investor Conferences

October 2025

29: Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

October 2025

29: Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

October 2025

29: Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

October 2025

28: Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

October 2025

28: Verily Accelerates Precision Health AI With NVIDIA

October 2025

27: Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 2025

27: Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

October 2025

26: Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

October 2025

26: Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

October 2025

25: Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

October 2025

25: Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

October 2025

24: Lilly to Acquire Adverum Biotechnologies

October 2025

24: Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

October 2025

23: Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

October 2025

23: Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

October 2025

23: Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

October 2025

22: Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

October 2025

21: Four years of progression-free survival: Nuvation Bio wins FDA approval for lung cancer

October 2025

20: Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2025

20: Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

October 2025

20: Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

October 2025

17: Verily Launches a New Consumer Health App, Verily Me, at HLTH USA 2025

October 2025

16: Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

October 2025

16: Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

October 2025

16: Avidity Biosciences to Participate in Upcoming Investor Conference

October 2025

16: Belite Bio to Participate in the 2025 Maxim Growth Summit

October 2025

15: Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

October 2025

15: enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 2025

15: FDA approvals - September 2025

October 2025

15: Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

October 2025

14: SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

October 2025

14: Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

October 2025

14: Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal’s Sellersville, Pennsylvania Site

October 2025

14: Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

October 2025

14: Affinia Therapeutics to Participate in Upcoming Investor Conferences

October 2025

14: Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

October 2025

14: Verily, UCHealth, University of Colorado Anschutz, and RefinedScience launch strategic collaboration for AI-powered research and care transformation

October 2025

13: Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control

October 2025

13: From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal

October 2025

13: Geron Corporation Announces Executive Leadership Transitions and Appointments

October 2025

13: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

October 2025

10: Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

October 2025

10: Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2025

9: New CEO of Kindbody David Stern is in the business of building families

October 2025

8: Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

October 2025

8: Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain